SCHEMBL5873713

SCHEMBL5873713

Cc1cc2cc([N+](=O)[O-])ccc2nc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.49
HTT P42858 3/20 0.49
ALDH1A1 P00352 4/20 0.49
TDP1 Q9NUW8 2/20 0.49
TSHR P16473 2/20 0.49
NPBWR1 P48145 7/20 0.47
TTR P02766 1/20 0.47
CYP3A4 P08684 2/20 0.46
HSD17B10 Q99714 1/20 0.44
TXNRD1 Q16881 1/20 0.44
TXNRD3 Q86VQ6 1/20 0.44
TXNRD2 Q9NNW7 1/20 0.44
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 3/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
OPRK1 P41145 1/20 0.43
MITF O75030 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27431081 0.83 ALDH1A1 (0.52) SMN1; SMN2HTTALDH1A1TDP1TSHR
Iodide SCHEMBL27670064 0.82 ALDH1A1 (0.50) SMN1; SMN2HTTALDH1A1TDP1TSHR
SCHEMBL6365630 0.81 KDM4E (0.45) SMN1; SMN2HTTALDH1A1NPBWR1HSD17B10
SCHEMBL24207775 0.81 ALDH1A1 (0.46) SMN1; SMN2HTTALDH1A1TDP1TSHR
SCHEMBL28025775 0.81 HSD17B10 (0.44) SMN1; SMN2HTTALDH1A1TDP1TSHR
SCHEMBL28756895 0.81 TDP1 (0.49) SMN1; SMN2HTTALDH1A1TDP1TSHR
SCHEMBL6365421 0.81 NPBWR1 (0.47) SMN1; SMN2HTTALDH1A1TDP1TSHR
SCHEMBL31444630 0.80 ALDH1A1 (0.51) SMN1; SMN2HTTALDH1A1TDP1NPBWR1
SCHEMBL6372099 0.78 KDM4E (0.51) SMN1; SMN2HTTALDH1A1NPBWR1HSD17B10
SCHEMBL31399941 0.78 CYP1A2 (0.55) SMN1; SMN2HTTALDH1A1TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084156-B2 2-Aminoquinoline compounds MERCK & CO., INC. (US) 2006-08-01 US disclosed
US-20050165006-A1 Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same HYUNDAI PHARM. IND. CO., LTD. (KR) 2005-07-28 US disclosed
US-20050026915-A1 2-Aminoquinoline compounds MERCK SHARP & DOHME CORP. 2005-02-03 US disclosed
EP-1450801-A2 2-AMINOQUINOLINE COMPOUNDS Merck & Co., Inc. (US) 2004-09-01 EP disclosed
WO-2003082286-A1 QUINOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME CHEMON INC. (KR) 2003-10-09 WO disclosed
WO-2003045313-A2 2-AMINOQUINOLINE COMPOUNDS MERCK & CO. INC. (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165006-A1 Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same SLC18A2, SLC6A4, SLC6A2 SMN1; SMN2 1739/4885HTT 419/4885ALDH1A1 3497/4885
US-20050026915-A1 2-Aminoquinoline compounds MCHR1, MCHR2, MC5R SMN1; SMN2 162/4885HTT 61/4885ALDH1A1 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.